跳至主要内容
临床试验/NCT02183714
NCT02183714已完成3 期

The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances

Boehringer Ingelheim0 个研究点目标入组 146 人开始时间: 1998年5月最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
146
主要终点
Change in sleep quality on a 100 mm visual analogue scale (VAS)

研究概览

简要总结

To evaluate the effect of Songha Night ® on insomnia, anxiety and quality of life compared to placebo in patients with mild to moderate insomnia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Psychophysiologic insomnia
  • Severity: mild to moderate
  • Duration: subacute to chronic
  • Subjects age > 18 and < 65, men or women
  • Subject had to give written informed consent

排除标准

  • Regular use of psycho-active drugs
  • Work in shifts
  • Use of psychoactive drugs during the past 30 days
  • Any treatment that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, psychiatric disorder, myasthenia gravis, delirious state, etc.)
  • known hypersensitivity to any of the ingredients of the study drug
  • Pregnancy, lactation, women of childbearing potential not using an established contraceptive
  • Drug and alcohol abuse
  • Participation in another trial within the past 30 days

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

Songha Night ®

Experimental

干预措施: Songha Night ® (Drug)

结局指标

主要结局

Change in sleep quality on a 100 mm visual analogue scale (VAS)

时间窗: baseline, after 2 and 4 weeks of treatment, 1 week after end of treatment

次要结局

  • Feeling refreshed score (six point rating scale)(up to week 5)
  • Ability to concentrate and perform well score (six point rating scale)(up to week 5)
  • Night-time total sleeping time(up to week 5)
  • Difficulty in falling asleep (five point rating scale)(up to week 5)
  • Number of awakenings during the night(up to week 5)
  • Physical and mental health state by short form (SF-36) questionnaire(up to week 5)
  • Anxiety by State-Trait Anxiety Inventory(up to week 5)
  • Frequency of adverse events(up to week 5)
  • Global clinical impression on insomnia by short questionnaire(up to week 5)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验